Fall 2016
Page 1 to 2 of 2 |
Cell and gene therapies - the emerging fourth pillar of healthcare systems By Keith Thompson
As the CEO of an organisation that deals exclusively in cell and gene therapies, it is no surprise that I would champion the emergence of these products as the fourth pillar of medicine alongside small molecules, biologics and devices.

Read More

Breath based biomarker detection - informing drug development & future treatment regimes By Billy Boyle and Dr Mike Murphy
The approval of liquid biopsy test for the diagnosis of non-small cell lung cancer (NSCLC) demonstrates how biomarker-based detection tools are becoming important components of precision medicine-based drug treatment regimes.

Read More

Fall 2016
Page 1 to 2 of 2 |